Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study

Antiviral Therapy

Volumn 20, Issue 3, 2015, Pages 343-348

  Akil, Bisher ^a   Blick, Gary ^b   Hagins, Debbie P ^c   Ramgopal, Moti N ^d   Richmond, Gary J ^e   Samuel, Rafik M ^f   Givens, Naomi ^g   Vavro, Cindy ^h   Song, Ivy H ^h   Wynne, Brian ^h   Ait Khaled, Mounir ^g  

^a PC   (United States)

^b CIRCLE CARE Center ^*  (United States)

^c Chatham County Health Department   (United States)

^d Midway Immunology and Research Center   (United States)

^e Broward Health   (United States)

^f TEMPLE UNIVERSITY   (United States)

^g GLAXOSMITHKLINE   (United Kingdom)

^h GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR PLUS RITONAVIR; DARUNAVIR PLUS RITONAVIR; DOLUTEGRAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; ETRAVIRINE; LOPINAVIR PLUS RITONAVIR; PLACEBO; RALTEGRAVIR; RITONAVIR PLUS TIPRANAVIR; TENOFOVIR DISOPROXIL; VIRUS RNA; ZIDOVUDINE; FUSED HETEROCYCLIC RINGS; INTEGRASE INHIBITOR;

ADULT; AGED; AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; DRUG EFFECTS; GENETICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; MIDDLE AGED; MUTATION; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD; YOUNG ADULT;

ADULT; AGED; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; FEMALE; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84937540880     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2878     Document Type: Article

References (8)

1. Tivicay (dolutegravir). Package insert 2013. ViiV Healthcare, Research Triangle Park, NC, USA.
2. Tivicay (dolutegravir). Summary of product characteristics 2013. ViiV Healthcare UK Ltd, Middlesex, UK.
3. Raffi F, Rachlis A, Stellbrink HJ, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet 2013; 381:735-743.
4. Cahn P, Pozniak AL, Mingrone H, et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integraseinhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet 2013; 382:700-708.
5. Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med 2013; 369:1807-1818.
6. Castagna A, Maggiolo F, Penco G, et al. Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. J Infect Dis 2014; 210:354-362.
7. Dooley KE, Sayre P, Borland J, et al. Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a Phase 1 study among healthy subjects. J Acquir Immune Defic Syndr 2013; 62:21-27.
8. Vavro C, Huang J, Avatapally C, et al. Durable efficacy and limited integrase resistance in subjects receiving dolutegravir after failing a prior INI regimen: week 48 results from VIKING-3. 12th European Workshop on HIV & Hepatitis Treatment Strategies & Antiviral Drug Resistance. 26-28 March 2014, Barcelona, Spain. Abstract O-10.